Evidence map›Paper›PMID 35846064›Full record

ArticleEJHaem2022

Long-term outcome of immunologic autograft engineering.

Luis F Porrata, David J Inwards, Stephen M Ansell, Ivana N Micallef, Patrick B Johnston, Jose C Villasboas, Jonas Paludo, Svetomir N Markovic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luis F PorrataDivision of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.ORCID https://orcid.org/0000-0001-5266-3226
David J InwardsDivision of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.
Stephen M AnsellDivision of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.
Ivana N MicallefDivision of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.
Patrick B JohnstonDivision of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.
Jose C VillasboasDivision of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.
Jonas PaludoDivision of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.ORCID https://orcid.org/0000-0002-7350-5531
Svetomir N MarkovicDepartment of Medical Oncology Mayo Clinic Rochester Minnesota USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our phase III trial reported that autograft-absolute lymphocyte count (A-ALC) improved survival post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short-term follow-up of 2 years. We evaluated retrospectively in our phase III trial patients that the A-ALC still confers survival benefit with a longer follow-up. With a median follow-up of 127.6 months, patients infused with an A-ALC ≥ 0.5 × 10

Indexed as

autograft absolute lymphocyte countautologous peripheral blood hematopoietic stem cell transplantationsurvival

Identifiers

PMID35846064
PMCPMC9176079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.